Comparative Pharmacology
Head-to-head clinical analysis: PERIACTIN versus PHENETRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PERIACTIN versus PHENETRON.
PERIACTIN vs PHENETRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyproheptadine is a first-generation antihistamine with anticholinergic and antiserotonergic properties. It acts as a competitive antagonist at histamine H1 receptors and serotonin 5-HT2 receptors, thereby inhibiting histamine-mediated allergic symptoms and serotonin-mediated effects such as increased gastrointestinal motility and vascular permeability.
Phenetron is an antihistamine that competes with histamine for H1-receptor sites, blocking histamine-mediated effects in the respiratory tract, vascular system, and gastrointestinal tract. It also exhibits anticholinergic and sedative properties.
4 mg orally three times daily; adjust as needed. Maximum: 32 mg/day.
Adults: 50 mg intramuscularly every 6 hours as needed.
None Documented
None Documented
10-12 hours terminal elimination half-life; steady-state reached in 2-3 days
Terminal half-life 12–15 hours; clinically, steady-state achieved in ~3 days
Renal (40-50% as metabolites, <5% unchanged); biliary/fecal (minor, ~10-20%)
Renal: ~70% unchanged; Biliary/Fecal: ~15% as metabolites; 15% unidentified
Category C
Category C
Antihistamine
Antihistamine